Sentinel node in oral cancer: the nuclear medicine aspects: a survey from the sentinel european node trial by Tartaglione, Girolamo et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Sentinel node in oral cancer: the nuclear medicine aspects: a survey from
the sentinel european node trial
Tartaglione, Girolamo; Stoeckli, Sandro J; de Bree, Remco; Schilling, Clare; Flach, Geke B; Bakholdt,
Vivi; Sorensen, Jens Ahm; Bilde, Anders; von Buchwald, Christian; Lawson, Georges; Dequanter,
Didier; Villarreal, Pedro M; Forcelledo, Manuel Florentino Fresno; Amezaga, Julio Alvarez; Moreira,
Augusto; Poli, Tito; Grandi, Cesare; Vigili, Maurizio Giovanni; O’Doherty, Michael; Donner, Davide;
Bloemena, Elisabeth; Rahimi, Siavash; Gurney, Benjamin; Haerle, Stephan K; Broglie, Martina A;
Huber, Gerhard F; Krogdah, Annelise l; Sebbesen, Lars R; Odell, Edward; Junquera Gutierrez, Luis
Manuel; et al
Abstract: PURPOSE: Nuclear imaging plays a crucial role in lymphatic mapping of oral cancer. This
evaluation represents a subanalysis of the original multicenter SENT trial data set, involving 434 pa-
tients with T1-T2, N0, and M0 oral squamous cell carcinoma. The impact of acquisition techniques,
tracer injection timing relative to surgery, and causes of false-negative rate were assessed. METHODS:
Three to 24 hours before surgery, all patients received a dose of Tc-nanocolloid (10-175 MBq), followed
by lymphoscintigraphy. According to institutional protocols, all patients underwent preoperative dy-
namic/static scan and/or SPECT/CT. RESULTS: Lymphoscintigraphy identified 723 lymphatic basins.
1398 sentinel lymph nodes (SNs) were biopsied (3.2 SN per patient; range, 1-10). Dynamic scan allowed
the differentiation of sentinel nodes from second tier lymph nodes. SPECT/CT allowed more accurate
anatomical localization and estimated SN depth more efficiently. After pathological examination, 9.9%
of the SN excised (138 of 1398 SNs) showed metastases. The first neck level (NL) containing SN+ was
NL I in 28.6%, NL IIa in 44.8%, NL IIb in 2.8%, NL III in 17.1%, and NL IV in 6.7% of positive patients.
Approximately 96% of positive SNs were localized in the first and second lymphatic basin visualized using
lymphoscintigraphy. After neck dissection, the SN+ was the only lymph node containing metastasis in
approximately 80% of patients. CONCLUSIONS: Best results were observed using a dynamic scan in
combination with SPECT/CT. A shorter interval between tracer injection, imaging, and surgery resulted
in a lower false-negative rate. At least 2 NLs have to be harvested, as this may increase the detection of
lymphatic metastases.
DOI: https://doi.org/10.1097/RLU.0000000000001241
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-133056
Published Version
Originally published at:
Tartaglione, Girolamo; Stoeckli, Sandro J; de Bree, Remco; Schilling, Clare; Flach, Geke B; Bakholdt,
Vivi; Sorensen, Jens Ahm; Bilde, Anders; von Buchwald, Christian; Lawson, Georges; Dequanter, Didier;
Villarreal, Pedro M; Forcelledo, Manuel Florentino Fresno; Amezaga, Julio Alvarez; Moreira, Augusto;
Poli, Tito; Grandi, Cesare; Vigili, Maurizio Giovanni; O’Doherty, Michael; Donner, Davide; Bloemena,
Elisabeth; Rahimi, Siavash; Gurney, Benjamin; Haerle, Stephan K; Broglie, Martina A; Huber, Gerhard
F; Krogdah, Annelise l; Sebbesen, Lars R; Odell, Edward; Junquera Gutierrez, Luis Manuel; et al (2016).
Sentinel node in oral cancer: the nuclear medicine aspects: a survey from the sentinel european node
trial. Clinical Nuclear Medicine, 41(7):534-542.
DOI: https://doi.org/10.1097/RLU.0000000000001241
2
Sentinel Node in Oral Cancer
The Nuclear Medicine Aspects. A Survey from the Sentinel European Node Trial
Girolamo Tartaglione, MD,* Sandro J. Stoeckli, MD,† Remco de Bree, MD,‡ Clare Schilling, MD,§
Geke B. Flach, MD,‡ Vivi Bakholdt, MD,|| Jens Ahm Sorensen, MD,|| Anders Bilde, MD,¶
Christian von Buchwald, MD,¶ Georges Lawson, MD,** Didier Dequanter, MD,††
Pedro M. Villarreal, MD,‡‡Manuel Florentino Fresno Forcelledo, MD,§§ Julio Alvarez Amezaga, MD,||||
Augusto Moreira, MD,¶¶ Tito Poli, MD,*** Cesare Grandi, MD,††† Maurizio Giovanni Vigili, MD,‡‡‡
Michael O’Doherty, MD,§§§ Davide Donner, MD,|||||| Elisabeth Bloemena, MD,¶¶¶
Siavash Rahimi, MD,**** Benjamin Gurney, MD,§ Stephan K. Haerle, MD,††††
Martina A. Broglie, MD,† Gerhard F. Huber, MD,‡‡‡‡ Annelise l. Krogdah, MD,§§§§
Lars R. Sebbesen, MD,¶ Edward Odell, MD,|||||||| Luis Manuel Junquera Gutierrez, MD,‡‡
Luis Barbier, MD,|||| Joseba Santamarıa-Zuazua, MD,|||| Manuel Jacome, MD,¶¶
Marie-Cecile Nollevaux, MD,¶¶¶¶ Emma Bragantini, MD,***** Philippe Lothaire, MD,††
Enrico M. Silini, MD,††††† Enrico Sesenna, MD,*** Giles Dolivet, MD,‡‡‡‡‡
Romina Mastronicola, MD,‡‡‡‡‡ Agnes Leroux, MD,§§§§§ Isabel Sassoon, MD,||||||||||
Philip Sloan, MD,¶¶¶¶¶ Patrick M. Colletti, MD,******
Domenico Rubello, MD,†††††† and Mark McGurk, MD§
Purpose:Nuclear imaging plays a crucial role in lymphatic mapping of oral
cancer. This evaluation represents a subanalysis of the original multicenter
SENT trial data set, involving 434 patientswith T1-T2, N0, andM0 oral squa-
mous cell carcinoma. The impact of acquisition techniques, tracer injection
timing relative to surgery, and causes of false-negative rate were assessed.
Methods: Three to 24 hours before surgery, all patients received a dose of
99mTc-nanocolloid (10–175 MBq), followed by lymphoscintigraphy. Accord-
ing to institutional protocols, all patients underwent preoperative dynamic/
static scan and/or SPECT/CT.
Results: Lymphoscintigraphy identified 723 lymphatic basins. 1398 senti-
nel lymph nodes (SNs) were biopsied (3.2 SN per patient; range, 1–10). Dy-
namic scan allowed the differentiation of sentinel nodes from second tier
lymph nodes. SPECT/CT allowed more accurate anatomical localization and
estimated SN depth more efficiently. After pathological examination, 9.9%
of the SN excised (138 of 1398 SNs) showed metastases. The first neck level
(NL) containing SN+ was NL I in 28.6%, NL IIa in 44.8%, NL IIb in 2.8%,
NL III in 17.1%, and NL IV in 6.7% of positive patients. Approximately 96%
of positive SNs were localized in the first and second lymphatic basin visu-
alized using lymphoscintigraphy. After neck dissection, the SN+ was the
only lymph node containing metastasis in approximately 80% of patients.
Conclusions: Best results were observed using a dynamic scan in combina-
tion with SPECT/CT. A shorter interval between tracer injection, imaging,
and surgery resulted in a lower false-negative rate. At least 2 NLs have to
be harvested, as this may increase the detection of lymphatic metastases.
Key Words: squamous cell carcinoma, sentinel lymph nodes,
lymphoscintigraphy, single-photon emission computed tomography,
head and neck cancer, gamma probe, sentinel lymph node biopsy,
lymphatic metastasis, neck dissection
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T he presence of lymph node metastases is generally the most im-portant prognostic factor in head and neck cancers.1 In oral
squamous cell carcinoma (OSCC), the prevalence of occult metas-
tases ranges from 15% to 35%.2 Unfortunately, even highly sophis-
ticated radiological imaging (CT, MRI, US, and PET/CT) is unable
to reliably detect or exclude small cervical metastases.3
Historically, management of T1-T2N0 OSCC was to per-
form an elective lymph node neck dissection (END),4–7 but this ap-
proach may result in overtreatment in up to 75% of patients. The
wait-and-see policy is not recommended because of the risk of ad-
vanced late metastases and difficult salvage surgery.8,9 In a recent
landmark paper comparing END to wait and see in a prospective
randomized trial, the patients undergoing END showed a clear sur-
vival benefit.10 There is a need to improve the detection of occult
lymph node metastases to offer END in only those patients that will
benefit from the procedure.11
Sentinel node biopsy (SNB) attempts to identify the regional
lymph nodes most likely to harbor metastasis. The sentinel node
(SN) is any lymph node or group of lymph nodes, which receives
lymphatic drainage directly from the primary tumor. Sentinel nodes
may not necessarily be the ones closest to the tumor, and usually,
there is more than one SN. All other lymph nodes are reached after
passing through the sentinel node and are therefore called second-
tier or second echelon lymph nodes.12
Sentinel node biopsy is universally recognized as an accu-
rate staging method in melanoma and breast cancer, reliably
selecting patients for lymph node dissection. In the 1990s, Pitman
first used intraoperative lymphatic mapping with isosulfan blue
dye for the detection of SNs in OSCC.13 The first successful
SNB in OSCC using a gamma probe was reported in 1996 by
Alex and Krag.14 Since then, an increasing number of validation
studies and observational trials have proven the applicability of
lymphoscintigraphy and SNB in OSCC with high sensitivity,
negative predictive value, and low regional failure rate in patients
with a negative SNB.15–25
From 2005 to 2010, a prospective European Sentinel Node
observational Trial (SENT) involving 14 European institutions
was conducted to establish the role of SNB in the management of
early OSCC.26 Sentinel nodes were mapped using lymphoscinti-
graphy, requiring a multidisciplinary approach involving nuclear
medicine physicians, surgeons, and pathologists in a variety of
practice settings.
The aim of this paper is to analyze the role and compare
methods of lymphoscintigraphy for lymphatic mapping and identi-
fication of the SN in OSCC in the SENT multicenter trial.
PATIENTS AND METHODS
From October 2005 to October 2010, approximately 482
consecutive patients with cT1-T2cN0 OSCC were recruited from
14 European centers in the SENT study. The study was approved
by the EORTC (No. 24021) protocol review committee in accor-
dance with local research ethics committee approval. This evalua-
tion represents a subanalysis of the original SENT data set with
emphasis on lymphoscintigraphic data. Forty-eight patients had in-
adequate data and were excluded from the analysis, leaving 434 el-
igible cases; some patients that did not follow the SENT protocol
and thus excluded from long-term follow-up analysis were included
in this nuclear medicine evaluation.
TABLE 1. Nuclear Medicine Procedures Applied
Procedures Tracer % of Patients
Radiopharmaceutical Nanocolloid 91%
NanoCis 9%
Same day Dose 47 MBq (10–94) 64%
Two day Dose 70 MBq (20–175) 36%
Volume mL 0.4 (0.2–1) 100%
Tracer injections 4 (2–6) 100%
Peritumoral injection 100%
Skin mark 93%
Timing Same day 64%
Two days 36%
Gamma Probe 100%
Mobile Camera 10%
3D Navigation 10%
Blue-dye 29%
Gamma camera 100%
Zoom x1.5 11%
x1.0 89%
Collimator LEAP 11%
LEHR 89%
Dynamic 78%
Frames 30”–60” in total 15’– 30’ 100%
Matrix 128  128 100%
STATIC 45%
Preset time 120”–300” 82%
600” 18%
Matrix 256  256 100%
SPECT 46%
Degree of rotation 360°(180°x2) 100%
Number of views 60* 35%
32 ** 33%
120 *** 33%
Time per view 15” * 35%
30”–40” ** 33%
8” *** 33%
Orbit Circular * *** 67%
Noncircular ** 33%
SPECT/CT 29%
FIGURE 1. Neck levels according to American Academy of
Otolaryngology–Head andNeck Surgery (picture homemade).
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All patients were staged N0 based on CTorMRI. Any lymph
nodes larger than 1.5 cm in level II and larger than 1 cm in all other
levels or lymph nodes with a round shape, central necrosis, and pe-
ripheral contrast enhancement were considered as pathological and
therefore excluded the patient from participation. No previous neck
pathology or treatment to the primary tumor or neck that could alter
lymphatic drainage channels had been performed.
All patients underwent injection of radiotracer and lymphoscin-
tigraphy imaging between 3 and 24 hours before surgery according
to local institutional protocols. Any jewelry, dental prosthesis, and
all relevant metallic items were removed. The position mirrored
that of the patient at surgery. The radiopharmaceuticals used in
our study were 99mTc-HSA Nanocoll (GE Healthcare) in 395
(91%) of 434 patients and 99mTc-Nanocis (CIS Bio) in 39 (9%)
of 434 patients. If necessary, a local anesthetic (10% lidocaine spray)
was given before injection to reduce patient discomfort. The average
dose of injected radioactivity was 47MBq (range, 10–94MBq) for a
same-day protocol and 70MBq (range, 23–175MBq), using a 2-day
protocol, respectively.
The radiotracer was diluted in a small volume of saline so-
lution, ranging from 0.2 to 1 mL.
The radiotracer was injected submucosally in 4 sites around
the tumor in an attempt to completely surround the border of the tu-
mor with the radiocolloid. A mouthwash was used immediately af-
ter injection to prevent pooling or swallowing of tracer.
Lymphoscintigraphy acquisition started within a few min-
utes of tracer injection and was initially monitored dynamically
with the gamma camera in the anterior view in 338 (78% extra)
of 434 patients.
Dynamic images for 5’–30’ (15”–30” frames; matrix, 128 
128) were acquired with a gamma camera equipped with a LEAP or
LEHR collimator, minimizing the distance from the collimator face
to the patient, to increase spatial resolution. The energy window of
20% was centred at 140 KeV, zoom 1.5, 128  128 or 256 
256 matrix.
In 195 (45%) of 434 patients, when accumulation of the ra-
diotracer in the first node(s) occurred, an early planar static scan
(256  256, preset time 300”–600”, zoom 1.0–1.5, collimator
LEAP or LEHR) was taken, followed by a lateral and/or oblique
view depending on the lymphatic drainage seen. The SNs were lo-
calized with the gamma camera using an external radioactive
marker (99mTc or 57Co) or with a flood-field source in anterior
and lateral projections. The skin overlying the SNs was marked
with an indelible marker pen in 404 (93%) of 434 patients to help
the surgeons localize the SN during surgery. SPECT imaging was
performed in 200 (46%) of 434 patients. SPECT acquisition pa-
rameters are described in Table 1.
A SPECT/CT system was used in 126 (29%) of 434 cases.
Unexpected lymphatic drainage patterns including unilateral
level IVor Voccurred in some tumors.
The surgeon used a hand-held gamma probe to detect the SN
in the area of the skin marks to direct the skin incision and to per-
form a radioguided SNB intraoperatively. Radioactivity was con-
firmed in the excised SN, and the cutoff value for an SN was at
least 3 times the background activity. After excision of all SNs,
the level of radioactivity in situ had to drop to background levels
to ensure excision of all SNs.
In 127 (29%) of 434 patients, additional intraoperative peri-
tumoral injections of Patent Blue V dye (~0.5 mL) were performed
in an identical manner to the injections of radiotracer. SNs were la-
beled according to their radioactivity count and anatomical neck level
according to the a classification system developed by the American
Academy of Otolaryngology–Head and Neck Surgery (Fig. 1).27
Sentinel nodes were histologically evaluated with step-serial
sectioning, staining with hematoxylin and eosin and immunohisto-
chemistry with a pan cytokeratin antibody AE1/3 according to the
modified Canniesburn protocol.28 Demographic data, site of pri-
mary tumor, lymphatic drainage patterns, anatomical location, and
number and order of appearance at lymphoscintigraphy of SNswere
collected for each patient. The collected data were subjected to uni-
variate statistical analysis.
RESULTS
In the SENT trial, 434 patients with OSCC staged cT1/T2cN0
(257 male and 177 female patients) with a mean age of 60.8 years
(range, 28–92 years) were eligible for the subanalysis of nuclear
medicine data.
The sites of the primary tumors and the results of the SNB are
shown in Table 2.
Tumor localization was well lateralized in 386 (89%) of
434 patients. The primary tumor was found on the right side in
199 (46%) of 434 patients, left side in 187 (43%) of 434 patients,
and in the midline in 48 (11%) of 434 patients, respectively. On
lymphoscintigraphy, the lymphatic drainage was unilateral in 361
(83%) of 434 patients and bilateral in 73 (17%) of 434 patients.
Unexpected lymphatic drainage patterns were observed in 69
(16%) of 434 patients.
TABLE 2. Tumor Location and SENTINEL Node Status
Site of Primary No. Patients (%) SNB– (%) SNB+ (%)
Anterior 2/3 tongue 218 (50.2) 158 (72.5) 60 (27.5)
Posterior 1/3 tongue 44 (10.1) 28 (63.6) 12 (27.4)
Buccal mucosa 19 (4.4) 15 (78.9) 4 (21.1)
Soft palate 10 (2.3) 8 (80.0) 2 (20.0)
FOM 110 (25.4) 91 (82.7) 19 (17.3)
Retro-molar 9 (2.1) 6 (66.7) 3 (33.3)
Lower alveolus 8 (1.8) 4 (50.0) 4 (50.0)
Upper alveolus 7 (1.6) 6 (85.7) 1 (14.3)
Lower lip 6 (1.4) 6 (100.0) 0 (0.0)
Hard palate 3 (0.7) 3 (100.0) 0 (0.0)
Total 434 (100.0) 329 (75.8) 105 (24.2)
TABLE 3. Lymphoscintigraphic Order of Appearance of SN According to Anatomical Neck Level (723 Lymphatic Basins
Dissected in 434 Patients)
Lymphatic Basins NL I NL IIa NL IIb NL III NL IV NLV N/A Total
Main basin 124 (28.6) 234 (53.9) 10 (2.3) 58 (13.4) 6 (1.4) 2 (0.4) 0 (0.0) 434 (59.9)
Second basin 36 (15.1) 61 (25.5) 12 (5.0) 94 (39.3) 19 (7.9) 11 (4.6) 6 (2.5) 239 (33.1)
Third basin 6 (13.0) 12 (26.1) 1 (0.2) 10 (21.7) 17 (36.9) 0 (0.0) 0 (0.0) 46 (6.4)
Fourth basin 0 (0.0) 1 (25.0) 0 (0.0) 1 (25.0) 0 (0.0) 2 (50.0) 0 (0.0) 4 (0.6)
Total 166 (22.9) 308 (42.6) 23 (3.2) 163 (22.5) 42 (5.8) 15 (2.0) 6 (1.0) 723 (100)
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In particular, bilateral lymphatic drainage was observed in
47of 386 patients with a well-lateralized tumor, and conversely, uni-
lateral lymphatic drainage was observed in 22 of 48 patients with a
midline tumor.
Using dynamic scintigraphy, a primary lymphatic basin was
identified in all patients in a mean time of 5 minutes (range up to
120). In 145 (33%) of 434 patients, there was just one basin identi-
fied. Two lymphatic basins were identified in 239 (55%) of
434 patients, in a mean time of 15 minutes (range up to 120). Three
lymphatic basins were identified in 46 (11%) of 434 patients, in a
mean time of 16 minutes (range up to 120). Four lymphatic basins
were identified in 4 (1%) of 434 cases.
Table 3 describes the anatomical location (NL) of the lym-
phatic basins as assessed using lymphoscintigraphy.
In total, 723 lymphatic basins were dissected with a mean of
1.7 (range, 1–4) lymphatic basins per patient. The classification of
first, second, third, or fourth lymphatic basins was based on the
timing of tracer appearance and intensity of uptake.
The average number of SNs removed per lymphatic basin
was 1.9 (range, 1–5). A total of 1398 radioactive SNs were removed
in 434 patients, resulting in a mean of 3.2 SNs per patient (range,
1–10). In the 73 patients with bilateral lymphatic drainage, themean
number of SNs was 3.9 (range, 2–10). The distribution of the SNs
within the neck levels (NL) is described in Table 4.
Only in 1 (0.2%) of 434 patients was the lymphoscintigraphy
technique ineffective and did not demonstrate an SN. After patho-
logical examination, 138 (9.9%) of 1398 SNs showed metastases.
The 135 positive SNs upstaged 105 (24.2%) of 434 patients. The
anatomical localization of positive SNs is shown in Table 5. Ap-
proximately 108 (78%) of 138 positive SNs were localized in the
main lymphatic basin, allowing identification of 89 (85%) of 105
positive patients. Approximately 24 (17%) of 138 positive SNswere
localized in the second lymphatic basin, allowing identification of
12 (11%) of 105 positive patients. The remaining 6 (4%) of 138
positive SNs were found in the third lymphatic basin, upstaging 4
(4%) of 105 patients. No positive tumor deposits were found in
the fourth lymphatic basin.
Neck dissection (ND) was performed in all 105 patients with
positive SNB. After ND, the positive SNs remained the only lymph
node containing metastases in 84 (80%) of 105 patients. In 127
(29%) of 434 patients, lymphoscintigraphy was combined with in-
traoperative injection of blue dye, and in this group, 392 radioactive
SNs were harvested. The SNs were “hot and blue” in 186 (47.4%)
of 392 cases, and only “hot” in 206 (52.6%) of 392 cases. The mean
number of SNs per patient removed with and without the use of blue
dye was 3.1 versus 3.2, respectively. This difference was not statis-
tically significant (P = 0.191).
The mean number of lymphatic basins biopsied was 1.6 in
the 1-day protocol 276 (64%) of 434 patients and 1.8 in the 2-day
protocol 158 (36%) of 434 patients. Similarly, the mean number
of SNs harvested per patient was 3.20 and 3.24. All these differ-
ences were not statistically significant (P = 0.240).
When considering if the number of lower echelon neck levels
were increased by a 2-day protocol, we found that biopsies were
taken from level IVand V in 6.3% of 1-day patients compared with
10.3% in 2-day patients (P = 0.498). Using a same-day protocol, the
false negative rate (FNR, percentage of cases in which a test fails to
detect the disease) was 10.8%, compared with 13.3% in the 2-day
protocol (P = 0.265) (Table 6).
SPECT imaging identified a mean of 3.29 SNs per patient
compared with 3.14 by planar lymphoscintigraphy. The FNR was
10.0% compared with 13.5%without SPECT (P = 0.297) (Table 7).
DISCUSSION
Sentinel node biopsy in OSCC is rapidly evolving after inno-
vation of new technologies. In the neck, there are normally more
than 300 lymph nodes, and sentinel nodes are often in proximity
to the injection area. Embedded in the epithelium of the oral cavity
mucosa, there are mainly blind ending lymphatic capillaries con-
nected to an underlying lymphatic plexus, which channels lymph
into deeper lymphatic vessels. These are then directed into the re-
gional lymph nodes.
TABLE 4. Location of SNs According to Appearance on Dynamic Lymphoscintigraphy
#SN/Neck Level #SN Main Basin #SN Second Basin #SN Third Basin #SN Fourth Basin #SN Total
NL I 291 (15.7) 70 (5.0) 9 (0.6) 0 (0.0) 370 (26.5)
NL IIa 481 (34.4) 106 (7.6) 14 (1.0) 2 (0.1) 603 (43.1)
NL IIb 18 (1.3) 19 (1.4) 1 (0.1) 0 (0.0) 38 (2.7)
NL III 104 (7.4) 157 (11.2) 13 (0.9) 2 (0.1) 276 (19.7)
NL IV 17 (1.2) 29 (2.1) 22 (1.6) 0 (0.0) 68 (4.8)
NLV 7 (0.5) 20 (1.4) 0 (0.0) 4 (0.4) 31 (2.2)
N/A 0 (0.0) 12 (0.8) 0 (0.0) 0 (0.0) 12 (1.0)
Total 918 (65.7) 413 (29.5) 59 (4.2) 8 (0.6) 1398 (100.0)
TABLE 5. Anatomical Localization, Number and Order of Tracer Appearance of Positive SNs in105 Patients With Lymphatic
Metastases
#SN+/Neck Level #SN+ Main Basin #SN+ Second Basin #SN+ Third Basin #SN+ Total First Neck Level Containing SN+
NL I 32 (23.2) 4 (2.9) 0 (0.0) 36 (26.1) 30 (28.6)
NL IIa 55 (39.9) 8 (5.8) 0 (0.0) 63 (45.7) 47 (44.8)
NL IIb 2 (1.4) 1 (0.7) 0 (0.0) 3 (2.1) 3 (2.8)
NL III 14 (10.1) 9 (6.5) 2 (1.4) 25 (18.1) 18 (17.1)
NL IV 5 (3.6) 2 (1.4) 4 (2.9) 11 (8.0) 7 (6.7)
Total 108 (78.3) 24 (17.4) 6 (4.3) 138 (100.0) 105 (100.0)
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Sometimes, there is more than one lymphatic channel originat-
ing in the region of the primary cancer and running to different lym-
phatic basins. Because of this complex arrangement, an experienced
team is required for optimal identification of SN in the head and neck.
Solitary use of the gamma probe for SN identification is dis-
couraged because it samples only one particular area for a short
time, and its sensitivity is lower than the gamma camera. Accurate
lymphatic mapping is crucial for correct identification of SNs, con-
sidering the individual and unpredictable lymphatic drainage pat-
terns of OSCC.29–31
Minimal requirements for adequate SNB are the use of
peritumoral radiotracer injection, preoperative lymphoscintigraphic
scanning and the use of a peroperative gamma probe.
These instruments allow for reliable lymphatic mapping and
SN localization and identification.
Selection of the radiotracer, availability of dynamic/static and
SPECT-CT lymphoscintigraphy, and type of gamma probe are de-
pendent on individual institutions’ resources. Many factors influ-
ence correct identification of SNs in OSCC.
An average activity of 47 MBq was injected for a same-day
protocol, whereas an average activity of 70 MBq was injected with
a 2-day protocol. The injection technique of tracer can impact on the
success rate of SNB. Intratumoral or deeper injection should be
avoided because intense bleeding at injection points may increase
background activity with low-quality images resulting in difficult
identification of SNs. Superficial perilesional injections of radio-
tracer are preferred to intratumoral or deeper injections because
the lymphatic capillary plexuses in the mucosa provide a larger sur-
face area for uptake with a faster lymph drainage and a better iden-
tification of lymph collecting vessels and SN in a shorter time.32–34
Colloidal radiopharmaceuticals are phagocytosed by the
macrophages within the lymph node, retaining the tracer in the
draining node. The higher signal-to-noise ratio facilitates gamma
probe identification of the SN. Normally, if the injection technique
is correct, themain lymphatic basin is demonstrated by dynamic im-
aging within a few minutes.
The value of blue dye injection is debatable. Data from the
SENT trial confirm a low concordance between blue dye and
lymphoscintigraphy. Blue dye and nanocolloids have different
pharmacokinetic and pharmacodynamic properties, and therefore,
results differ as well. Blue dye moves rapidly downstream to distal
lymph nodes, whereas nanocolloids are more efficiently trapped,
achieving a superior identification rate.
Planar lymphoscintigraphy is routinely used for preoperative
sentinel node localization. Gamma cameras have the advantage of
simultaneously sampling multiple lymph node basins in the entire
neck, with improved staging. A LEAP/LEGP collimator, which in-
creases the sensitivity of the gamma camera, and an adequate zoom
factor (1.5) may be able to demonstrate lymphatic drainage path-
ways and SNs closely related to the primary tumor (Fig. 2).
Dynamic planar imaging in the anterior view may show indi-
vidual lymph drainage pathways demonstrating the direction of
lymphatic drainage. In our trial, 96% of positive SNs were localized
at the main or second tier lymphatic basin, confirming the impor-
tance of this approach.
Static planar images in lateral/oblique views show an over-
view of the number and localization of SNs. The levels of these
SNs can be further localized using external radioactive markers,
such as a 99mTc or a 57Co-source pen for marking the overlying skin
or a 57Co flood source transmission scan.
Lymphoscintigrams demonstrated the large variability and
complexity of lymphatic drainage patterns in OSCC. Themain lym-
phatic basin is specific for each patient regardless of the site of pri-
mary tumor. This personalized lymphatic mapping reveals an
unexpected lymphatic drainage pattern in 16% of patients with con-
tralateral drainage in well-lateralized tumors or unilateral drainage
in midline tumors. This considerable number confirms the impor-
tance of lymphoscintigraphy before surgery. This unexpected drain-
age would not have been sampled by routine END.
In some patients, level I, IIa, or III lymph nodes can be con-
nected with the primary cancer in series or directly by an individual
lymphatic collector (Fig. 3). This may explain why, in some cases,
metastases can bypass nodes near the primary cancer and can be
found in a higher (oftenmore caudal) neck level. However, the shine
through phenomenon may simulate this finding.
SPECTwas performed in addition to planar images with the
principal purpose of anatomical localization of SNs already identi-
fied using lymphoscintigraphy.
FIGURE 2. SCCof tongue 2/3 anterior: the early scan in the left lateral view shows the injection point and the lymphatic drainage
way directed toward a SN at NL IL; from this SN, we can see 2 lymphatic ways directed toward the NL IIa and the NL III. The
distal lymph node (NL III) seems to be connected with cancer area in series and in parallel.
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FIGURE 3. Images show different lymphatic drainage patterns, in 4 patients with an SCC of the oral cavity. A, early scan (5’)
shows a single lymphatic way directed toward a SN localized at NL IIa (right side). B, Early scan (5’) shows 2 lymphatic ways
directed toward a SN localized at NL IIa and toward a SN localized at NL III (right side).C, Late scan (30’) in anterior view shows a
bilateral lymphatic drainagewith SNs and second tier lymph nodes at lower neck levels.D, Late scan (30’) in the left lateral view
shows the SNs at NLs I, II, and III.
FIGURE 4. SPECT-CT imaging in OSCC: the image shows a SN at NL I.
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For more accurate lymphatic mapping, an early scan with
oblique views and/or SPECT is required to identify SNs that are
closely related to the primary cancer. An interesting trendwas found
using SPECT imaging: 25.7% of level 1 nodes were biopsied, in-
stead of 16.5% found in the group of patients studied without
SPECT. In addition, in the group of cases studied with SPECT,
the FNR was 10% compared with 13.5% in the group of patients
studied without SPECT. These findings may also be attributed to
the shine through phenomenon, throughwhich NL I SNs can be dif-
ficult to identify.
In floor-of-mouth cancer, it is suggested that the primary tu-
mor is excised before performing SNB to reduce the shine-through
phenomenon as radioactivity at the primary site may obscure SN lo-
cated at NL I.35
Fused SPECT/CT imagingmay allowmore accurate anatom-
ical localization of the SNs adjacent to the primary lesion (Fig. 4).
Sometimes, SPECT/CT may result in more visible foci and, there-
fore, more SNs. If these are in greater proximity to the primary tu-
mor site, the additional SNs may have clinical relevance.36–39
Dynamic scan is recommended to identify the velocity from
the injection site to the first echelon node as well as the ap-
pearance of the other echelon-nodes. The association with
SPECT/CT acquisition following the static planar imaging
appears to be very useful to better lobalize the site of the senti-
nel node(s) as suggested by current EANM-SENT joint practice
guidelines and by a recent Phase III Multi-institutional Trial
on OSCC.33,40
Variable intervals of time between tracer injection, imaging,
and surgery were used in this study.With regard to the timing of sur-
gery, we observed that 63.6% of patients had a same-day protocol,
whereas 36.4% had a 2-day protocol.
The same-day protocol resulted in a high percentage of lym-
phatic basins being dissected closely to the primary (I-III NLs) of
93.2% as compared with 88.6% using a 2-day protocol. There
was no statistically significant difference between the 2 groups re-
garding the mean number of lymphatic basins biopsied and the
mean number of SNs harvested per patient. Using a same-day pro-
tocol, the FNR was 10.8%. Using a 2-day protocol, we observed
10.3% of lower NLs (IV, V) biopsied versus 6.3% with a same-
day protocol. This approach resulted in an FNR of 13.3%. The ra-
diotracer may appear progressively with time in second-tier lymph
nodes that have a lower incidence of metastases. The same-day
protocol may be a more advantageous approach because fewer
nonrelevant SNs were sampled, although no significant differences
were found.
In patients with neck dissections, SNs were the only lymph
nodes containing metastasis in approximately 80% of positive pa-
tients, confirming the high sensitivity of SN sampling and the as-
sumption that a primary tumor drains to relatively few lymph nodes
before disseminating to the remaining local nodal field.
In our trial, we observed that 96% of positive SNswere local-
ized in the first and second lymphatic basin as visualized using dy-
namic scanning. The anatomical localization of 92% of positive
SNs were in I, IIa, IIb, and III NLs. For these reasons, accurate lym-
phatic mapping and perioperative probe scanning of these NLs is
always recommended.
New technologies such as a mobile camera or 3D navigation
were used in only 10% of cases.
These new technological approaches may aid intraoperative
identification of SNs. Freehand SPECT is a 3D tomographic nu-
clear imaging modality based on the concepts of SPECT, which
can be used for intraoperative visualization of SNs to facilitate their
localization and removal during surgery.41
Indocyanine green (ICG) fluorescence for SN biopsy has
been used in relatively few cases, and its role is under study. The
use of ICG in combination with 99mTc (hybrid tracer) may provide
additional information to detect SNs in head and neck cancer.42,43
In conclusion, SNB is the most advanced, multidisciplinary
and continuously evolving strategy available to reduce the risk from
occult lymph node metastases in cT1/T2N0 OSCC patients and
may play a crucial role in the decision on whether to perform neck
dissection in clinical practice.
From this study, it can be concluded that a dynamic planar im-
aging is essential to differentiate between SNs and second echelon
nodes; SPECT/CT may be helpful in anatomical localization of the
SNs. A same-day protocol may be better able to identify only the
most relevant (sentinel) lymph nodes. The value of blue dye in addi-
tion to radiolabeled nanocolloids is limited. At the least, biopsy of
SNs in the first and second lymphatic basin appears to be necessary.
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